Hepatic arterial infusion versus intravenous oxaliplatin in a safety, feasibility and pharmacokinetic study of liver-dominant malignancies – ARTEMIS OXYS-I trial
Sponsor: Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Phase: 1
Disease: Intrahepatic cholangiocarcinoma, Colorectal liver metastases
EU trial number: 2026-527509-39-01
Population: Adults with histologically confirmed unresectable intrahepatic cholangiocarcinoma or colorectal liver metastases, ECOG performance status 0–1, adequate organ function, and either a functioning hepatic arterial infusion pump from a prior PUMP trial or eligibility for percutaneous hepatic arterial infusion. Patients with dominant extrahepatic metastatic disease are excluded.
Register Investigator Interest
Interested in offering this trial to suitable patients?